GSIAS
VTGN icon

Garden State Investment Advisory Services’s VistaGen Therapeutics VTGN Stock Holding History

Garden State Investment Advisory Services’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,000
Closed -$3.74K – 271
2023
Q1 		$3.74K Hold
1,000
– – ﹤0.01% 224
2022
Q4 		$3.09K Buy
+1,000
New +$3.76K ﹤0.01% 196

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Cubist Systematic Strategies
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Garden State Investment Advisory Services's VTGN Position: Q2 2023 in Review

Garden State Investment Advisory Services sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 1,000 shares — an estimated $3.74K sold.

Garden State Investment Advisory Services first reported a position in VTGN in Q4 2022 and held it in 2 quarters. The position peaked at $3.74K in Q1 2023. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • Garden State Investment Advisory Services reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Garden State Investment Advisory Services sold 1,000 VistaGen Therapeutics shares in Q2 2023, an estimated $3.74K.
  • Garden State Investment Advisory Services first reported a position in VistaGen Therapeutics in Q4 2022 and held it in 2 quarters.
  • Garden State Investment Advisory Services's VistaGen Therapeutics position peaked at $3.74K in Q1 2023.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Garden State Investment Advisory Services's 13F filing for Q2 2023, filed 14 Aug 2023.